Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

Plain-language guide to PMID 34653252 (2022): open-label clinical trial, phase ii study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone), hyperparathyroidism.

Key Facts

PMID: 34653252
Journal: The Journal of clinical endocrinology and metabolism
Year: 2022
Study type: Clinical Trial, Phase II
Authors: Auchus RJ et al. (11 authors)
DOI: 10.1210/clinem/dgab749

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in the context of hyperparathyroidism, published as a clinical trial, phase ii.

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is characterized by impaired cortisol synthesis and excess androgen production.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.

Participants included men and women, aged 18 to 50 years, with 21OHD.

Participants could enroll in more than 1 cohort.

How the Study Was Run

In design terms this was a open-label study.

Being open-label, the ACTH (Corticotropin) study did not mask who received what.

This open-label, phase 2 study, with sequential cohort design (NCT03525886), took place in 6 centers in the United States.

Main outcomes included changes from baseline to day 14 in adrenocorticotropin (ACTH), 17-hydroxyprogesterone (17OHP), androstenedione, and testosterone.

What Was Measured

The subject headings attached to it are 17-alpha-Hydroxyprogesterone, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Androstenedione, Azabicyclo Compounds, Biomarkers and Oxadiazoles.

The authors tagged it with the keywords 17-hydroxyprogesterone, 21-hydroxylase deficiency, NBI-74788, congenital adrenal hyperplasia and crinecerfont.

What This Means in Plain Language

The paper is an open-label study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in people with hyperparathyroidism.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the ACTH (Corticotropin) compound page and the CRH (Corticotropin-Releasing Hormone) compound page, Hyperparathyroidism research.

Our Notes on the Compounds

ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).

CRH (Corticotropin-Releasing Hormone): The 41-amino-acid hypothalamic hormone that triggers ACTH release; corticorelin is used diagnostically.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.